Search results
Results from the WOW.Com Content Network
This contamination was not detected until 2018. The incident, according to medicinal chemist and pharmaceutical industry blogger Dr. Derek Lowe, points to a greater problem. Generic drug manufacturers often change the way in which prescription drug ingredients are made in order to lower costs of making them, so this kind of contamination may be ...
Scrip Intelligence (Scrip) is an English language international pharmaceutical news, analysis and data service. First published as a weekly print newsletter in March 1972, Scrip included articles on side-effects, regulatory changes and mergers and acquisitions.
They publish WebMD the Magazine, a patient-directed publication distributed bimonthly free of charge to 85 percent of physician waiting rooms. [13] Medscape is a professional portal for physicians and has training materials, a drug database, and clinical information on 30 medical specialty areas and more than 30 physician discussion boards. [ 14 ]
Data mining pharmacovigilance databases is one approach that has become increasingly popular with the availability of extensive data sources and inexpensive computing resources. The data sources (databases) may be owned by a pharmaceutical company, a drug regulatory authority, or a large healthcare provider.
Lizzie Haldane, Min Young Park, and Eric Tang for help with data collection. Jessica Wisdom Carnegie Mellon University 208 Porter Hall Pittsburgh, PA 15213 jwisdom@cmu.edu (412) 268-2869 Julie Downs Carnegie Mellon University 208 Porter Hall Pittsburgh, PA 15213 downs@cmu.edu (412) 268-1862 George Loewenstein Carnegie Mellon University
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by the British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. [1]
Total costs—including $51 million for “public relations, grants, sales support and medical education programs,” and $14.3 million for free samples—were budgeted at just $103 million. That included the salaries of all the salespeople and the cost of the drug itself, which was so low that it did not merit its own line item.
To sit in the back of the room watching the impeccably dressed, articulate men and women who are orchestrating Johnson & Johnson’s trailblazing cures for cancer, Alzheimer’s, diabetes, AIDS and mental illness, and to watch the Wall Street crowd digesting it and calculating the potential cash flows and returns on investment, was to watch the free market dream come true.